Altimmune announces successful completion of multiple dose toxicity and toxicokinetic studies of alt-801, a glp-1/glucagon dual receptor agonist for the treatment of nash

Company anticipates first-in-human trials to start in q4 2020 company anticipates first-in-human trials to start in q4 2020
ALT Ratings Summary
ALT Quant Ranking